This large observational study identifies patient demographics and specific medication choices (e.g., topiramate vs. naltrexone) as significant predictors of early discontinuation of FDA-approved medications for alcohol use disorder, highlighting a critical adherence gap in clinical practice.
This case report highlights postpartum delirious mania in a bipolar patient, demonstrating that while valproate and olanzapine are used for maintenance, electroconvulsive therapy (ECT) is critical for rapid symptom resolution when pharmacotherapy fails.
A case report describes temporary restoration of cognitive and functional abilities in an 80-year-old Alzheimer's patient following a single high dose of psilocybin, highlighting potential therapeutic avenues for dementia.
The Chicago VA Hospital has initiated a psilocybin-assisted therapy program for veterans with PTSD, reflecting evolving clinical approaches to this treatment modality.
A 'nudging' strategy in the emergency department increases prescriptions of alcohol-use-disorder medications, offering a practical method to expand access to pharmacotherapy for AUD.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 11 – Jun 10)
- Consider electroconvulsive therapy (ECT) as a critical intervention for rapid symptom resolution in postpartum delirious mania when pharmacotherapy fails.
- Monitor valproate levels closely when initiating lurasidone in bipolar I patients, as subtherapeutic mood stabilizer levels increase the risk of manic switching even with atypical antipsychotics.
- Utilize 'nudging' strategies in emergency department settings to increase prescriptions of alcohol-use-disorder medications and improve access to pharmacotherapy.
- Recognize that medication choice significantly impacts early discontinuation rates for alcohol use disorder, with topiramate and naltrexone showing distinct adherence profiles based on patient demographics.
- Consider adjunctive N-acetylcysteine to accelerate symptom reduction in obsessive-compulsive disorder patients who remain symptomatic on high-dose sertraline, particularly targeting obsessions.
- Be aware that regulatory hurdles may delay the availability of new once-daily ADHD treatments like CTx-1301, requiring reliance on existing pharmacotherapies.
- Evaluate potential off-label applications of psilocybin for behavioral symptoms in advanced dementia, noting case reports of transient functional improvement following high doses.
- Anticipate evolving clinical pathways for PTSD treatment as institutions begin implementing psilocybin-assisted therapy programs for veterans.
Clinical Pearl 2
A case report documents a switch to mania following lurasidone initiation in a bipolar I patient with subtherapeutic valproate levels, highlighting the risk of antidepressant-like switching even with atypical antipsychotics when mood stabilizers are inadequate.
A double-blind trial suggests adjunctive N-acetylcysteine accelerates symptom reduction in OCD patients on high-dose sertraline, particularly for obsessions, though it does not improve cognitive functioning.
Diagnosis & Treatment 1
A case report describes transient functional improvement in advanced Alzheimer's disease following high-dose psilocybin, highlighting potential off-label psychopharmacologic applications for dementia behavioral symptoms.
Policy & Regulation 1
The FDA issued a complete response letter for Cingulate's once-daily ADHD drug CTx-1301, indicating regulatory hurdles in its development pathway.